Ebglyss™ (lebrikizumab-lbkz) – New drug approval
August 23, 2024 - The FDA approved Amgen’s Pavblu (aflibercept-ayyh), biosimilar to Regeneron’s Eylea® (aflibercept).
August 23, 2024 - The FDA approved Amgen’s Pavblu (aflibercept-ayyh), biosimilar to Regeneron’s Eylea® (aflibercept).